- InMed Pharmaceuticals press release ( NASDAQ: INM ): Q2 GAAP EPS of -$0.91.
- Revenue of $0.47M (+74.1% Y/Y).
- Approaches completion of enrollment for Ph 2 clinical trial in EB
- Advances research using rare cannabinoids in treating glaucoma and neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s.
- At December 31, 2022, the Company’s cash, cash equivalents and short-term investments were $11.5 million, which compares to $6.2 million at June 30, 2022.
- Shares +6.25% AH.
For further details see:
InMed Pharmaceuticals GAAP EPS of -$0.91, revenue of $0.47M